1. 807PProlonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. (23rd October 2018) Authors: Tombal, B; Hussain, M; Penson, D; Attard, G; Sternberg, C N; Phung, D; Morlock, R; Modelska, K; Ramaswamy, K; Ivanescu, C; Saad, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 813PTreatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment. (23rd October 2018) Authors: Robbrecht, D G; van Soest, R J; Tannock, I F; Oudard, S; Tombal, B; Eisenberger, M; Mercier, F; de Wit, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 826PUse of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. (23rd October 2018) Authors: Sternberg, C N; Tombal, B; Miller, K; Saad, F; Sartor, O; Sade, J P; Logothetis, C; Bellmunt, J; Dizdarevic, S; Harshman, L C; Logue, J; Baldari, S; Richardson, T; Bottomley, D; Schostak, M; Bayh, I; Kalinovsky, J; Higano, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 827PClinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Higano, C S; Tombal, B; Miller, K; Saad, F; Sartor, O; Tangirala, K; Jiao, X; Kalinovsky, J; Sternberg, C N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 9PPlasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial. (7th November 2019) Authors: Jayaram, A K; Shen, D; Wingate, A; Wetterskog, D; Sternberg, C; Jones, R; Berruti, A; Lefresne, F; Lahaye, M; Thomas, S; Joshi, S; Gormley, M; Tombal, B; Merseburger, A; Ricci, D; Attard, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. (10th September 2018) Authors: Armstrong, A J; Lin, P; Higano, C S; Sternberg, C N; Sonpavde, G; Tombal, B; Templeton, A J; Fizazi, K; Phung, D; Wong, E K; Krivoshik, A; Beer, T M Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (19th November 2019) Authors: Horwich, A; Babjuk, M; Bellmunt, J; Bruins, H M; Reijke, T M De; Santis, M De; Gillessen, S; James, N; Maclennan, S; Palou, J; Powles, T; Ribal, M J; Shariat, S F; Kwast, T Van Der; Xylinas, E; Agarwal, N; Arends, T; Bamias, A; Birtle, A; Black, P C Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. LBA30ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). (23rd October 2018) Authors: Smith, M R; Parker, C C; Saad, F; Miller, K; Tombal, B; Ng, Q S; Bögemann, M; Matveev, V; Piulats, J M; Zucca, L E; Heidenreich, A; Kakehi, Y; Zhang, A; Krissel, H; Shen, J; Wagner, V; Higano, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗